Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04185311
Title Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Ipilimumab + Nivolumab + Talimogene laherparepvec

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.